Koninklijke Philips (NYSE:PHG) Position Reduced by Bonness Enterprises Inc.

Bonness Enterprises Inc. decreased its position in shares of Koninklijke Philips (NYSE:PHG - Free Report) by 15.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 88,062 shares of the technology company's stock after selling 15,755 shares during the quarter. Koninklijke Philips comprises about 0.8% of Bonness Enterprises Inc.'s investment portfolio, making the stock its 23rd largest holding. Bonness Enterprises Inc.'s holdings in Koninklijke Philips were worth $2,230,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Rhumbline Advisers boosted its stake in Koninklijke Philips by 5.3% during the 2nd quarter. Rhumbline Advisers now owns 28,170 shares of the technology company's stock valued at $710,000 after purchasing an additional 1,420 shares during the period. American Century Companies Inc. grew its holdings in Koninklijke Philips by 39.3% in the 2nd quarter. American Century Companies Inc. now owns 176,136 shares of the technology company's stock worth $4,439,000 after buying an additional 49,678 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Koninklijke Philips by 27.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 4,036,336 shares of the technology company's stock worth $101,718,000 after buying an additional 864,951 shares in the last quarter. Mercer Global Advisors Inc. ADV raised its stake in Koninklijke Philips by 5.9% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 95,620 shares of the technology company's stock valued at $2,410,000 after acquiring an additional 5,289 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC boosted its position in Koninklijke Philips by 15.1% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 42,140 shares of the technology company's stock worth $1,062,000 after acquiring an additional 5,522 shares during the period. Institutional investors own 13.67% of the company's stock.

Koninklijke Philips Price Performance

Shares of PHG traded up $0.75 during midday trading on Tuesday, reaching $26.55. The stock had a trading volume of 626,695 shares, compared to its average volume of 517,325. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.16 and a quick ratio of 0.74. The company has a market capitalization of $24.95 billion, a P/E ratio of -63.21, a P/E/G ratio of 0.86 and a beta of 0.77. The firm's 50 day moving average price is $25.84 and its 200-day moving average price is $28.09. Koninklijke Philips has a 52 week low of $19.55 and a 52 week high of $32.91.

Analyst Ratings Changes

A number of research analysts have recently commented on PHG shares. Jefferies Financial Group raised Koninklijke Philips from an "underperform" rating to a "hold" rating in a report on Tuesday, October 29th. StockNews.com downgraded shares of Koninklijke Philips from a "buy" rating to a "hold" rating in a research report on Thursday, November 14th. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold".

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.